A Multicenter, Double Blind, Randomized, Placebo Controlled Study to Measure the Effect of FX06 (a Fibrin Derived Peptide Bbeta15-42) on Ischemia Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention (PCI): The `F.I.R.E.' Study

Trial Profile

A Multicenter, Double Blind, Randomized, Placebo Controlled Study to Measure the Effect of FX06 (a Fibrin Derived Peptide Bbeta15-42) on Ischemia Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention (PCI): The `F.I.R.E.' Study

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs FX 06 (Primary)
  • Indications Myocardial infarction; Myocardial reperfusion injury
  • Focus Therapeutic Use
  • Acronyms FIRE
  • Most Recent Events

    • 06 Nov 2012 Planned number of patients changed from 140 to 220 as reported by European Clinical Trials Database record.
    • 31 Mar 2009 Results of a prespecified subgroup analysis investigating effects of time to therapy were presented at the American College of Cardiology (ACC-2009).
    • 24 Feb 2009 Results are published in Journal of the American College of Cardiology 53: 720-729, No. 8, 24 Feb 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top